Product logins

Find logins to all Clarivate products below.


Aliaksei Holik

Director for Discovery and Translational Science Consulting

Aliaksei is a biomedical scientist with over 15 years of experience in research, specializing in the use of computational biology and machine learning to unravel disease mechanisms, identify and validate therapeutic targets, and prioritize patient populations most likely to benefit from these therapies. With a strong background in Molecular Biology and Genetics, he has utilized a wide array of omics technologies throughout the entire research lifecycle, from experimental design and data generation to analysis and translating results into actionable insights.

As Director for Discovery and Translational Science Consulting Services, Aliaksei assists clients, ranging from top pharmaceutical companies to stealth-mode biotechs in their drug discovery and translational research efforts. His support encompasses data curation, management, and analytics services applied to pre-clinical and clinical datasets in order to understand disease and drug action mechanisms, prioritize targets and indications, and identify molecular and clinical biomarkers to pinpoint patient populations with the most favourable response and safety profiles.

Aliaksei holds a PhD in Cancer Biology from Cardiff University and a BSc in Molecular Biology from the University of Edinburgh.

Latest news

News May 21, 2026
Clarivate’s IPfolio and Renewal Services Selected by IGT

Managing global intellectual property more efficiently with trusted data, expert support and integrated services London, U.K. May 21, 2026: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today…

News May 19, 2026
Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility London, U.K. May 19, 2026: Clarivate Plc (NYSE:CLVT), a…

News May 13, 2026
Clarivate Identifies Five Medtech Trends Set to Redefine Growth Opportunities in 2026

New Medtech Trends to Watch report highlights market shifts, care delivery changes and competitive dynamics poised to reshape medtech strategy London, U.K.  May 13, 2026. Clarivate Plc (NYSE:CLVT), a leading…

Related resources

How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center